公司概覽
業務類別 Drug Manufacturers - Specialty & Generic
業務概覽 Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
公司地址 1000 Mylan Boulevard, Canonsburg, PA, USA, 15317
電話號碼 +1 724 514-1800
傳真號碼 --
公司網頁 https://www.viatris.com
員工數量 30000
 
公司高管 / 董事會成員
公司高管
高管 職務 年薪 更新日期
Dr. Corinne Le Goff, Pharm.D. Chief Commercial Officer 美元 605.77K 24/10/2025
Mr. Matthew J. Maletta Chief Legal Officer -- 03/02/2026
Mr. Paul B. Campbell Chief Accounting Officer and and Corporate Controller 美元 715.39K 26/02/2026
Mr. Scott A. Smith Director and Chief Executive Officer 美元 1.40M 26/02/2026
Ms. Theodora Mistras Chief Financial Officer 美元 809.14K 26/02/2026
Mr. Andrew Enrietti Chief Administrative and Transformation Officer -- 24/10/2025
 
董事會成員
董事會 職務 更新日期
Mr. Frank D’Amelio Independent Director 26/02/2026
Mr. Harry A. Korman Independent Director 05/05/2025
Dr. Michael Severino, M.D. Independent Director 26/02/2026
Mr. James M. Kilts Independent Director 26/02/2026
Mr. Leo Groothuis Independent Director 26/02/2026
Mr. Rajiv Malik Director 05/05/2025
Mr. Wyllie Don Cornwell Independent Director 26/02/2026
Mr. Mark W. Parrish Vice Chairman of the Board 26/02/2026
Ms. Melina E. Higgins Chairman of the Board 26/02/2026
Mr. David S. Simmons Independent Director 26/02/2026
Ms. JoEllen Lyons Dillon Independent Director 26/02/2026
Dr. Rogerio Vivaldi Coelho, M.B.A.,M.D. Independent Director 26/02/2026
Mr. Richard A. Mark, C.P.A. Independent Director 26/02/2026
Ms. Elisha W. Finney Independent Director 26/02/2026
Mr. Scott A. Smith Director and Chief Executive Officer 26/02/2026
 
所屬ETF (更新日期: 07/03/2026 02:24)
代號 名稱 佔比% 持有日期
AVUSAvantis US Equity ETF0.07%28/02/2026
PRFInvesco RAFI US 1000 ETF0.07%27/02/2026
PPHVanEck Pharmaceutical ETF0.06%28/02/2026
FLQMFranklin US Mid Cap Mltfctr Idx ETF0.06%28/02/2026
SCHBSchwab US Broad Market ETF™0.06%28/02/2026
IYHiShares US Healthcare ETF0.06%28/02/2026
SEIVSEI Enhanced US Large Cap Value Fac ETF0.06%27/02/2026
VONVVanguard Russell 1000 Value ETF0.05%31/01/2026
SCHVSchwab US Large-Cap Value ETF™0.05%28/02/2026
IXJiShares Global Healthcare ETF0.05%28/02/2026
XPHState Street® SPDR® S&P® PhrmctlsETF0.05%27/02/2026
FHLCFidelity MSCI Health Care ETF0.05%28/02/2026
RWLInvesco S&P 500 Revenue ETF0.04%27/02/2026
BBMCJPMorgan BetaBuilders US Mid Cap Eq ETF0.04%27/02/2026
USVMVictoryShares US Sm Md Cp Val Momt ETF0.04%27/02/2026
RECSColumbia Research Enhanced Core ETF0.04%04/02/2026
DHSWisdomTree US High Dividend ETF0.04%27/02/2026
SMMDiShares Russell 2500 ETF0.03%28/02/2026
DFUSDimensional US Equity Market ETF0.03%27/02/2026
IWViShares Russell 3000 ETF0.03%28/02/2026
  1    2   3    4    5  
 

Copyright © 2026 ET Net Limited.
All rights reserved. Use of this site signifies your agreement to the terms of use.
DISCLAIMER: ET Net Limited and Third Party Information Providers endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.